Skip to main content

Von Willebrand Disease

Registry of Patients With Von WilLEbrand Disease Treated With Voncento®
NCT04657887 | PHASE 3 | OBSERVATIONAL

Description of the long-term evolution of patients with von Willebrand disease and treated with Voncento® and of the hemostatic efficacy in the prevention and the treatment of non-surgical bleeding episodes and prevention of surgical bleeding during 2 years after patient inclusion.

Trial Information
17 Sites
135 Participants
Recruiting
2 Years to 11 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

CHU Besanon
Besançon,France
CHU Bordeaux
Bordeaux,France
CHU Morvan Brest
Brest,France
CHU Lyon
Bron,France
CHU Caen
Caen,France
Hpital Simone Veil
Eaubonne,France
Hpital Mignot
Le Chesnay,France
Hpital Bictre
Le Kremlin-Bicêtre,France
Hpital SaintEloi
Montpellier,France
CHRU Nancy
Nancy,France
CHU Nantes
Nantes,France
CHU Lariboisire
Paris,France
Hpital Cochin
Paris,France
Hpital Necker
Paris,France
CHU Rennes
Rennes,France
CHU Rouen
Rouen,France
CHU Strasbourg
Strasbourg,France

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov